October 17, 2018

Immusoft Receives Rare Pediatric Disease Designation For Treatment Of MPS I

October 3, 2018

VelosBio raises $58M in Series A round for antibody-drug conjugate development

September 12, 2018

Oncternal Announces First Patient Dosed in Phase 1b Clinical Trial of Cirmtuzumab in Combination with Paclitaxel in Patients with Breast Cancer

July 24, 2018

Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics

July 10, 2018

Jason Fontenot, Ph.D., Joins Immusoft As Chief Scientific Officer

July 9, 2018

Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate

June 1, 2018

Oncternal Announces Publication of Data from Phase 1 Trial of Cirmtuzumab in CLL in Cell Stem Cell

May 3, 2018

SelectION Appoints Antonius Schuh as New CEO

May 2, 2018

Immusoft Granted Orphan Drug Designation For Treatment Of Rare Childhood Disease

December 12, 2017

Telephus Biosciences Appoints Patrick Vink, M.D., MBA, William Boyle, Ph.D., and Richard Proctor, M.D., as Company Advisors